The German Inflammatory Bowel Disease Study Group (GISG) was established in November 2008 and emerged from a joint initiative of the German Group on IBD (DACED) and the Competence Network IBD, with the underlying aim to integrate all IBD treatment centres, i.e. medical practices, clinics and universities.

THE GISG

provides sustained support for research and treatment in the field of IBD

answers practice related clinical questions

invites all members to participate actively in addressing scientific questions

co-ordinates, jointly develops and implements research studies (IIT’s) in medical practices, clinics and universities

is a point of contact for international co-operation partners

GISG MEMBERS

Currently, the GISG has over 170 members, representing 135 study centres in Germany

GISG STRUCTURE

PLENARY ASSEMBLY OF THE GISG MEMBERS

Admission condition for GISG membership: general interest and potential to participate actively in GISG clinical studies

Plenary meeting is to be held twice a year

Plenary meeting selects the Board

BOARD

13 members

Election by the Plenary Assembly of at least:

• 2 independent medical practitioners
• 2 doctors from non-university hospitals
• 2 doctors from university hospitals
• 1 member of the Competence Network Board

Current GISG Board:

O. Bachmann
B. Bokemeyer
J. Büning
S. Fichtner-Feigl
J. Hampe
U. Helwig
T. Kühbacher
C. Maaser
J. Maul
C. Schmidt
B. Siegmund
S. Schreiber
A. Stallmach

Advisory GISG Board Members:

C. Sander
German Crohn’s and Colitis Association (DCCV e.V.)

P. Hartmann,
J. Zemke
Association for IBD Assistance (FA-CED e.V.)

PANEL OF SPOKESPERSONS

3 members

Elected from the Board

B. Siegmund, U. Helwig, J. Hampe

GISG ADMINISTRATIVE OFFICE

Office of the Panel of Spokespersons

M. Blömacher

SELECTED GISG PUBLICATIONS

• Adherence to the H1N1 vaccination recommendation in patients with Crohn’s disease or ulcerative colitis (Teich N et al., Dtsch med Wochenschr., 2011)
• Azathioprine-induced acute pancreatitis in patients with IBD - A prospective study on incidence and severity (Teich N et al., J Crohns Colitis, 2016)
• Cyclophosphamide pulse therapy in severe refractory Crohn’s disease: A retrospective multicenter case series (Bär F, Büning J et al., Inflamm Intest Dis, 2017)
• Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis (Büning J., Bär F, Fellermann K, APT, 2017)
• Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD. (Teich N., Bokemeyer B., Mohl W., Walldorf J., Bruns T., Schmidt C., Stallmach A., Gut, 2017)

SELECTED GISG TRIALS


Prevalence of cutaneous adverse events following initiation of anti-TNF-therapies in IBD patients - A national experience throughout all care levels

Pathogen spectrum and resistance patterns of intra-abdominal abscesses in Crohn’s Disease patients

Early monitoring of response on Golimumab therapy with fecal calprotectin and trough serum levels in patients with Ulcerative Colitis

Observational study on the risk of relapse after discontinuing TNF-blockers in Crohn’s Disease patients

Registry for patients with refractory celiac disease in Germany

Do thumb-sucking and nail-biting protect against IBD-development?

Registry for fistel-associated carcinoma in Crohn’s Disease patients

Discussion / Evaluation in the GISG Board

Recruitment / Documentation

Statistical Evaluation

GISG Administrative Office

Competence Network for Intestinal Diseases

Hopfenstr. 60
D-24103 Kiel / Germany

Phone: +49 431 592 957 3937
Fax: +49 431 592 957 3988
info@gisg.eu

www.gisg.eu
The German Inflammatory Bowel Disease Study Group (GISG) was established in November 2008 and emerged from a joint initiative of the German Group on IBD (DACED) and the Competence Network IBD, with the underlying aim to integrate all IBD treatment centres, i.e. medical practices, clinics and universities.

GISG STRUCTURE

**PLENARY ASSEMBLY OF THE GISG MEMBERS**

Admission condition for GISG membership: general interest and potential to participate actively in GISG clinical studies

Plenary meeting is to be held twice a year

Plenary meeting selects the Board

**BOARD**

13 members

Election by the Plenary Assembly of at least:

- 2 independent medical practitioners
- 2 doctors from non-university hospitals
- 2 doctors from university hospitals
- 1 member of the Competence Network Board

**Current GISG Board:**

- O. Bachmann
- B. Bokemeyer
- J. Büning
- S. Fichtner-Feigl
- J. Hampe
- U. Helwig
- T. Kühbacher
- C. Maaser
- J. Maul
- C. Schmidt
- B. Siegmund
- S. Schreiber
- A. Stallmach

**Advisory GISG Board Members:**

- C. Sander
- German Crohn’s and Colitis Association (DCCV e.V.)
- P. Hartmann,
- J. Zemke
- Association for IBD Assistance (FA-CED e.V.)

**PANEL OF SPOKESPERSONS**

3 members

Elected from the Board

B. Siegmund, U. Helwig, J. Hampe

**GISG ADMINISTRATIVE OFFICE**

Office of the Panel of Spokespersons

M. Blömacher

**SELECTED GISG MEMBERS**

Currently, the GISG has over **170** members, representing **135** study centres in Germany

**SELECTED GISG PUBLICATIONS**

- Adherence to the H1N1 vaccination recommendation in patients with Crohn’s disease or ulcerative colitis (Teich N et al., *Dtsch med Wochenschr.*, 2011)
- Azathioprine-induced acute pancreatitis in patients with IBD - A prospective study on incidence and severity (Teich N et al., *J Crohns Colitis*, 2016)
- Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis (Büning J, Bär F, Fellermann K, APT, 2017)

**SELECTED GISG TRIALS**

<table>
<thead>
<tr>
<th>Year</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathogen spectrum and resistance patterns of intra-abdominal abscesses in Crohn’s Disease patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early monitoring of response on Golimumab therapy with fecal calprotectin and trough serum levels in patients with Ulcerative Colitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observational study on the risk of relapse after discontinuing TNF-blockers in Crohn’s Disease patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Registry for patients with refractory celiac disease in Germany</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Do thumb-sucking and nail-biting protect against IBD-development?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Registry for fistel-associated carcinoma in Crohn’s Disease patients.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Discussion / Evaluation in the GISG Board**

**Recruitment / Documentation**

**Statistical Evaluation**
The German Inflammatory Bowel Disease Study Group (GISG) was established in November 2008 and emerged from a joint initiative of the German Group on IBD (DACED) and the Competence Network IBD, with the underlying aim to integrate all IBD treatment centres, i.e. medical practices, clinics and universities.

**THE GISG**

- Provides sustained support for research and treatment in the field of IBD
- Answers practice related clinical questions
- Invites all members to participate actively in addressing scientific questions
- Co-ordinates, jointly develops and implements research studies (RIt’s) in medical practices, clinics and universities
- Is a point of contact for international co-operation partners

**GISG STRUCTURE**

**PLENARY ASSEMBLY OF THE GISG MEMBERS**

- Admission condition for GISG membership: general interest and potential to participate actively in GISG clinical studies
- Plenary meeting is to be held twice a year
- Plenary meeting selects the board

**BOARD**

13 members

- Election by the Plenary Assembly of at least:
  - 2 independent medical practitioners
  - 2 doctors from non-university hospitals
  - 2 doctors from university hospitals
  - 1 member of the Competence Network Board

**Current GISG Board:**

- O. Bachmann
- B. Bokemeyer
- J. Büning
- S. Fichtner-Feigl
- J. Hampe
- U. Helwig
- T. Kühbacher
- C. Maaser
- S. Schreiber
- B. Siegmund
- S. Schrötter
- A. Stallmach

**Advisory GISG Board Members:**

C. Sander

German Crohn’s and Colitis Association (DCCV e.V.)

P. Hartmann, J. Zemke

Association for IBD Assistance (FA-CED e.V.)

**PANEL OF SPOKESPERSONS**

3 members

Elected from the Board

- B. Siegmund
- U. Helwig
- J. Hampe

**GISG ADMINISTRATIVE OFFICE**

Office of the Panel of Spokespersons

M. Blömacher

O. Bachmann

B. Bokemeyer

J. Büning

S. Fichtner-Feigl

J. Hampe

U. Helwig

T. Kühbacher

C. Maaser

J. Maul

C. Schmidt

B. Siegmund

S. Schreiber

A. Stallmach

**SELECTED GISG PUBLICATIONS**

- Adherence to the H1N1 vaccination recommendation in patients with Crohn’s disease or ulcerative colitis (Teich N et al., Dtsch med Wochenschr., 2011)
- Azathioprine-induced acute pancreatitis in patients with IBD - A prospective study on incidence and severity (Teich N et al., J Crohns Colitis, 2016)
- Cyclophosphamide pulse therapy in severe refractory Crohn’s disease: A retrospective multicenter case series (Bär F, Büning J et al., Inflamm Intest Dis, 2017)
- Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis (Büning J, Bär F, Fellermann K, APT, 2017)

**SELECTED GISG TRIALS**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Early monitoring of response on Golimumab therapy with fecal calprotectin and trough serum levels in patients with Ulcerative Colitis</td>
<td>Pathogen spectrum and resistance patterns of intra-abdominal abscesses in Crohn’s Disease patients</td>
<td>Observational study on the risk of relapse after discontinuing TNF-blockers in Crohn’s Disease patients</td>
<td>Registry for patients with refractory celiac disease in Germany</td>
<td>Do thumb-sucking and nail-biting protect against IBD-development?</td>
<td>Registry for fistel-associated carcinomas in Crohn’s Disease patients</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**GISG Administrative Office**

Competence Network for Intestinal Diseases
Hopfenstr. 60
D-24103 Kiel / Germany
Phone: +49 431 592 957 3937
Fax: +49 431 592 957 3988
info@gisg.eu

www.gisg.eu
The German Inflammatory Bowel Disease Study Group (GISG) was established in November 2008 and emerged from a joint initiative of the German Group on IBD (DACED) and the Competence Network IBD, with the underlying aim to integrate all IBD treatment centres, i.e. medical practices, clinics and universities.

**THE GISG**

- provides sustained support for research and treatment in the field of IBD
- answers practice related clinical questions
- invites all members to participate actively in addressing scientific questions
- co-ordinates, jointly develops and implements research studies (RfTs) in medical practices, clinics and universities
- is a point of contact for international cooperation partners

**GISG STRUCTURE**

- **PLENARY ASSEMBLY OF THE GISG MEMBERS**
  - Admission condition for GISG membership: general interest and potential to participate actively in GISG clinical studies
  - Plenary meeting is to be held twice a year
  - Plenary meeting selects the Board

- **BOARD**
  - 13 members
  - Election by the Plenary Assembly of at least:
    - 2 independent medical practitioners
    - 2 doctors from non-university hospitals
    - 2 doctors from university hospitals
    - 1 member of the Competence Network Board

- **Current GISG Board**
  - O. Bachmann
  - B. Bokemeyer
  - J. Büning
  - S. Fichtner-Feigl
  - J. Hampe
  - U. Helwig
  - T. Kühbacher
  - C. Maaser
  - J. Maul
  - C. Schmidt
  - A. Stallmach

- **Advisory GISG Board Members**
  - C. Sander
  - German Crohn’s and Colitis Association (DCCC e.V.)
  - P. Hartmann,
  - J. Zemke
  - Association for IBD Assistance (FA-CED e.V.)

- **PANEL OF SPOKESPERSONS**
  - 3 members
  - Elected from the Board
  - B. Siegmund, U. Helwig, J. Hampe

**GISG ADMINISTRATIVE OFFICE**

- Office of the Panel of Spokespersons
  - M. Blömacher

**GISG MEMBERS**

Currently, the GISG has over **170** members, representing **135** study centres in Germany.

**SELECTED GISG PUBLICATIONS**

- Adherence to the H1N1 vaccination recommendation in patients with Crohn’s disease or ulcerative colitis (Teich N et al., Dtsch med Wochenschr. 2011)
- Azathioprine-induced acute pancreatitis in patients with IBD - A prospective study on incidence and severity (Teich N et al., J Crohns Colitis. 2016)
- Cyclophosphamide pulse therapy in severe refractory Crohn’s disease: A retrospective multicenter case series (Bär F, Büning J et al., Inflamm Intest Dis. 2017)
- Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis (Büning J., Bär F, Fellermann K, APT, 2017)
- Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD - A prospective study on incidence and severity (Teich N et al., J Crohns Colitis. 2016)
- Azathioprine-induced acute pancreatitis in patients with IBD - A prospective study on incidence and severity (Teich N et al., J Crohns Colitis. 2016)
- Cyclophosphamide pulse therapy in severe refractory Crohn’s disease: A retrospective multicenter case series (Bär F, Büning J et al., Inflamm Intest Dis. 2017)
- Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis (Büning J., Bär F, Fellermann K, APT, 2017)
- Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD - A prospective study on incidence and severity (Teich N et al., J Crohns Colitis. 2016)

**SELECTED GISG TRIALS**

- Pathogen spectrum and resistance patterns of intra-abdominal abscesses in Crohn’s Disease patients
- Early monitoring of response on Golimumab therapy with fecal calprotectin and trough serum levels in patients with Ulcerative Colitis
- Observational study on the risk of relapse after discontinuing TNF-blockers in Crohn’s Disease patients
- Registry for patients with refractory colitis disease in Germany
- Do thumb-sucking and nail-biting protect against IBD-development?
- Registry for fistel-associated carcinoma in Crohn’s Disease patients
- Discussion / Evaluation in the GISG Board
- Recruitment / Documentation
- Statistical Evaluation

**GISG Administrative Office**

Competition Network for Inestinal Diseases
Hopfenstr. 60
D-24103 Kiel / Germany
Phone: +49 431 592 957 3937
Fax: +49 431 592 957 3988
info@gisg.eu